{"id":"2-chlorodeoxyadenosine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Nausea and vomiting"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Fatigue"},{"rate":"5-15%","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL4594368","moleculeType":"Small molecule","molecularWeight":"525.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By incorporating into DNA, 2-chlorodeoxyadenosine causes DNA strand breaks and triggers apoptosis in rapidly dividing cells, such as lymphocytes. This mechanism is particularly effective against certain types of leukemia.","oneSentence":"2-chlorodeoxyadenosine is a purine nucleoside analog that inhibits DNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:24.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"},{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT06463587","phase":"PHASE3","title":"Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-06-25","conditions":"Generalized Myasthenia Gravis","enrollment":264},{"nctId":"NCT06561360","phase":"PHASE2","title":"A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-09","conditions":"Hairy Cell Leukemia","enrollment":86},{"nctId":"NCT06021600","phase":"PHASE1","title":"A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-09","conditions":"Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT04375631","phase":"PHASE1","title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-03","conditions":"Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome","enrollment":120},{"nctId":"NCT07053020","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2027-12-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":58},{"nctId":"NCT05797740","phase":"","title":"Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2023-08-03","conditions":"Multiple Sclerosis","enrollment":367},{"nctId":"NCT04708054","phase":"PHASE2, PHASE3","title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-21","conditions":"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome","enrollment":324},{"nctId":"NCT01515527","phase":"PHASE2","title":"Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-07","conditions":"Leukemia","enrollment":160},{"nctId":"NCT06415864","phase":"","title":"Oral Cladribine B-cell Study","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2019-07-01","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT05906914","phase":"PHASE2","title":"Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-10-26","conditions":"Acute Myeloid Leukemia, Adult","enrollment":65},{"nctId":"NCT06660368","phase":"PHASE2","title":"BCL2i CLAG-M in R/R Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-26","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML)","enrollment":52},{"nctId":"NCT07278934","phase":"NA","title":"Testing the Impact of Family-Based Intervention to Improve Developmental and Health Outcomes for Female Adolescents","status":"NOT_YET_RECRUITING","sponsor":"New York University","startDate":"2026-02-15","conditions":"Unaccompanied Migration","enrollment":1920},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT03933202","phase":"","title":"A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-07-22","conditions":"Multiple Sclerosis","enrollment":291},{"nctId":"NCT05365035","phase":"PHASE2","title":"A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-23","conditions":"Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia","enrollment":60},{"nctId":"NCT07311746","phase":"PHASE1, PHASE2","title":"Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-01","conditions":"T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia","enrollment":36},{"nctId":"NCT05657652","phase":"NA","title":"CAV Regimen for R/R Ph- B-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":36},{"nctId":"NCT00412594","phase":"PHASE2","title":"Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-06-10","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia","enrollment":150},{"nctId":"NCT06232655","phase":"PHASE2","title":"Cladribine Venetoclax in Monocytic AML","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-02-08","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT04047641","phase":"PHASE1, PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-22","conditions":"Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":80},{"nctId":"NCT07032727","phase":"PHASE2","title":"Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-12","conditions":"Targeted Therapy, IDH1-Mutated Malignancies, Mutations","enrollment":68},{"nctId":"NCT04178005","phase":"PHASE4","title":"Cladribine Tablets After Treatment With Natalizumab (CLADRINA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2020-02-19","conditions":"Multiple Sclerosis","enrollment":40},{"nctId":"NCT03589729","phase":"PHASE2","title":"Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-09-19","conditions":"Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells","enrollment":100},{"nctId":"NCT06532552","phase":"PHASE2","title":"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-29","conditions":"Acute Myeloid Leukemia, Adult, Newly Diagnosed","enrollment":172},{"nctId":"NCT02115295","phase":"PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-05-19","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":508},{"nctId":"NCT04848974","phase":"PHASE1, PHASE2","title":"Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-06-11","conditions":"Secondary Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT04797767","phase":"PHASE1, PHASE2","title":"Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-02-04","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":62},{"nctId":"NCT03068819","phase":"PHASE1, PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-10-23","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT03586609","phase":"PHASE2","title":"Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-25","conditions":"Acute Myeloid Leukemia","enrollment":145},{"nctId":"NCT02250937","phase":"PHASE2","title":"Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":116},{"nctId":"NCT04695080","phase":"PHASE2, PHASE3","title":"ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-06-25","conditions":"Advanced Multiple Sclerosis, Progressive Multiple Sclerosis","enrollment":204},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT06504459","phase":"PHASE2","title":"Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-01-03","conditions":"Acute Monocytic Leukemia, Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT00923013","phase":"PHASE2","title":"Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-10-20","conditions":"Hairy Cell Leukemia","enrollment":175},{"nctId":"NCT06474663","phase":"PHASE1","title":"A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-31","conditions":"Refractory Acute Leukemia, Relapsed Acute Leukemia","enrollment":""},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT03477500","phase":"PHASE3","title":"Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2018-03-21","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT04934800","phase":"","title":"Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2019-12-10","conditions":"Multiple Sclerosis","enrollment":256},{"nctId":"NCT03963375","phase":"PHASE4","title":"Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-10-28","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":47},{"nctId":"NCT06887426","phase":"","title":"Cladribine Tablets as an Exit Therapy Strategy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-06","conditions":"Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":450},{"nctId":"NCT02205762","phase":"PHASE2, PHASE3","title":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","status":"RECRUITING","sponsor":"North American Consortium for Histiocytosis","startDate":"2016-11-02","conditions":"Langerhans Cell Histiocytosis","enrollment":1400},{"nctId":"NCT04050280","phase":"PHASE2","title":"CLAG-GO for Patients With Persistent, Relapsed or Refractory AML","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2019-11-01","conditions":"Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":39},{"nctId":"NCT03933215","phase":"","title":"A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-05-21","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT04861207","phase":"PHASE2","title":"Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maria Sklodowska-Curie National Research Institute of Oncology","startDate":"2021-10-07","conditions":"Acute Myeloid Leukemia Myelodysplastic Syndromes","enrollment":40},{"nctId":"NCT05766514","phase":"PHASE2","title":"Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2025-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT03150004","phase":"PHASE2","title":"Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2017-06-14","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":53},{"nctId":"NCT06561152","phase":"PHASE1, PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-02-10","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06060782","phase":"PHASE1","title":"Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine","status":"RECRUITING","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-03-06","conditions":"Burkitt Lymphoma, Lymphoblastic Lymphoma, Adult, Acute Lymphoblastic Leukemia, Adult","enrollment":28},{"nctId":"NCT04783935","phase":"PHASE4","title":"Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-03-10","conditions":"Multiple Sclerosis","enrollment":219},{"nctId":"NCT06763666","phase":"PHASE4","title":"CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-02","conditions":"Relapsed/Refractory AML","enrollment":172},{"nctId":"NCT04121403","phase":"PHASE3","title":"Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2019-10-16","conditions":"Relapsing Multiple Sclerosis, Multiple Sclerosis","enrollment":267},{"nctId":"NCT03441048","phase":"PHASE1","title":"Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-05-22","conditions":"Acute Myeloid Leukemia","enrollment":26},{"nctId":"NCT02096055","phase":"PHASE2","title":"Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-04-04","conditions":"Untreated Adult Acute Myeloid Leukemia","enrollment":44},{"nctId":"NCT02157181","phase":"PHASE2","title":"Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab","status":"COMPLETED","sponsor":"Jurgen Barth","startDate":"2004-06","conditions":"Hairy Cell Leukemia (HCL)","enrollment":89},{"nctId":"NCT02131753","phase":"PHASE2, PHASE3","title":"Therapy Optimisation for the Treatment of Hairy Cell Leukemia","status":"RECRUITING","sponsor":"University of Giessen","startDate":"2004-05","conditions":"Hairy Cell Leukemia","enrollment":210},{"nctId":"NCT06007911","phase":"PHASE1","title":"Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2024-08-31","conditions":"Relapsed Adult AML, Refractory AML","enrollment":""},{"nctId":"NCT04776213","phase":"PHASE4","title":"Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-02-23","conditions":"Multiple Sclerosis","enrollment":280},{"nctId":"NCT04121065","phase":"","title":"Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)","status":"RECRUITING","sponsor":"Neuromed IRCCS","startDate":"2020-09-07","conditions":"Relapsing Multiple Sclerosis","enrollment":150},{"nctId":"NCT03745144","phase":"PHASE1","title":"Effects of Cladribine Tablets on the PK of Microgynon®","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2019-01-17","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":28},{"nctId":"NCT05902429","phase":"PHASE4","title":"Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"Pontificia Universidade Católica do Rio Grande do Sul","startDate":"2021-04-28","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":10},{"nctId":"NCT04196010","phase":"PHASE1","title":"Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-05-08","conditions":"Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT06133556","phase":"PHASE2","title":"Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-11-24","conditions":"Acute Myeloid Leukemia","enrollment":237},{"nctId":"NCT03961204","phase":"PHASE4","title":"Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-08-15","conditions":"Multiple Sclerosis (MS)","enrollment":662},{"nctId":"NCT03369665","phase":"PHASE4","title":"Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-06-20","conditions":"Multiple Sclerosis","enrollment":485},{"nctId":"NCT03531918","phase":"PHASE1, PHASE2","title":"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-09-14","conditions":"Acute Myeloid Leukemia","enrollment":66},{"nctId":"NCT05961644","phase":"PHASE2, PHASE3","title":"Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).","status":"RECRUITING","sponsor":"Institute of Psychiatry and Neurology, Warsaw","startDate":"2022-10-03","conditions":"Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis","enrollment":188},{"nctId":"NCT05313958","phase":"PHASE2, PHASE3","title":"Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2021-12-01","conditions":"Leukemia, Monocytic, Acute, Pediatric AML","enrollment":43},{"nctId":"NCT02728050","phase":"PHASE1, PHASE2","title":"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-12-01","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome","enrollment":84},{"nctId":"NCT05330377","phase":"PHASE1","title":"GM-CLAG in Relapsed/Refractory FLT3-mutated AML","status":"WITHDRAWN","sponsor":"Ayman H Qasrawi","startDate":"2023-03","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT00199030","phase":"PHASE2","title":"Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath","status":"COMPLETED","sponsor":"Goethe University","startDate":"2004-02","conditions":"Adult Acute Lymphocytic Leukemia T-cell, Lymphoma, Lymphoblastic","enrollment":8},{"nctId":"NCT03364036","phase":"PHASE4","title":"Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-05-28","conditions":"Multiple Sclerosis","enrollment":270},{"nctId":"NCT03585686","phase":"PHASE2","title":"A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2018-06-26","conditions":"Langerhans Cell Histiocytosis","enrollment":12},{"nctId":"NCT05762003","phase":"","title":"Czech Pharmaco-epidemiological Study on Disease Modifying Drugs","status":"COMPLETED","sponsor":"IMPULS Endowment Fund","startDate":"2019-01-01","conditions":"Multiple Sclerosis","enrollment":17478},{"nctId":"NCT05578378","phase":"PHASE2, PHASE3","title":"Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-01-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":32},{"nctId":"NCT04676204","phase":"","title":"Relationship Between Oral DMT Burden and Adherence in MS","status":"ENROLLING_BY_INVITATION","sponsor":"Monash University","startDate":"2020-09-25","conditions":"Multiple Sclerosis, Adherence, Medication","enrollment":323},{"nctId":"NCT00198991","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-04","conditions":"Adult Acute Lymphocytic Leukemia","enrollment":1883},{"nctId":"NCT05466318","phase":"PHASE3","title":"ChiCGB vs BEAM in High-risk or R/R Lymphomas","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2022-07-01","conditions":"Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell","enrollment":306},{"nctId":"NCT05330364","phase":"PHASE2","title":"Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Ge Zheng","startDate":"2021-06-01","conditions":"Acute Myeloid Leukemia","enrollment":31},{"nctId":"NCT05053425","phase":"NA","title":"Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML","status":"UNKNOWN","sponsor":"LanZhou University","startDate":"2021-10-20","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT04640818","phase":"","title":"Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy","status":"UNKNOWN","sponsor":"Claudio Gobbi","startDate":"2020-12-17","conditions":"Multiple Sclerosis","enrollment":45},{"nctId":"NCT05250362","phase":"PHASE1, PHASE2","title":"Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2022-03-01","conditions":"Hematologic Malignancy","enrollment":56},{"nctId":"NCT03012672","phase":"PHASE2","title":"Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-12-30","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":50},{"nctId":"NCT00667329","phase":"PHASE1","title":"Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1999-07-09","conditions":"Lymphoma","enrollment":14},{"nctId":"NCT04550455","phase":"PHASE4","title":"A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets","status":"UNKNOWN","sponsor":"Keith Edwards, M.D.","startDate":"2020-09-16","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT02756572","phase":"PHASE2","title":"Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-09-22","conditions":"Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Neoplasm","enrollment":30},{"nctId":"NCT03384212","phase":"PHASE3","title":"CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-08-01","conditions":"High Risk Acute Myeloid Leukemia, Allogeneic Hematopoeitic Stem Cell Transplantation","enrollment":120},{"nctId":"NCT03384225","phase":"PHASE3","title":"CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-08-01","conditions":"High Risk Acute Myeloid Leukemia, Allogeneic Hematopoeitic Stem Cell Transplantation","enrollment":120},{"nctId":"NCT03257241","phase":"PHASE3","title":"A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old","status":"UNKNOWN","sponsor":"Polish Adult Leukemia Group","startDate":"2017-07-03","conditions":"Acute Myeloid Leukemia","enrollment":582},{"nctId":"NCT04880746","phase":"PHASE3","title":"Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2020-10-17","conditions":"Peripheral T-cell Lymphoma","enrollment":266},{"nctId":"NCT00725985","phase":"PHASE3","title":"Oral Cladribine in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2008-12-31","conditions":"Multiple Sclerosis","enrollment":617},{"nctId":"NCT01473797","phase":"PHASE2","title":"Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-11","conditions":"Langerhans Cell Histiocytosis of Lung","enrollment":10},{"nctId":"NCT04679506","phase":"","title":"the Efficacy and Safety of CLAE in R/R T-ALL/LBL","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2020-12","conditions":"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","enrollment":50},{"nctId":"NCT04254640","phase":"PHASE2","title":"Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-03-01","conditions":"Acute Myeloid Leukemia, Elderly Patients, Newly Diagnosed","enrollment":34},{"nctId":"NCT00641537","phase":"PHASE3","title":"CLARITY Extension Study","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2008-02-29","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":867},{"nctId":"NCT00436826","phase":"PHASE2","title":"A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2006-11-30","conditions":"Multiple Sclerosis","enrollment":172},{"nctId":"NCT02921061","phase":"PHASE1, PHASE2","title":"Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-11-17","conditions":"Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT02416908","phase":"PHASE1, PHASE2","title":"Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-06-16","conditions":"Acute Myeloid Leukemia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":639,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["2-CdA","Cladribin®","Leustatin®"],"phase":"phase_2","status":"active","brandName":"2-chlorodeoxyadenosine","genericName":"2-chlorodeoxyadenosine","companyName":"North American Consortium for Histiocytosis","companyId":"north-american-consortium-for-histiocytosis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"2-chlorodeoxyadenosine is a purine nucleoside analog that inhibits DNA synthesis. Used for Acute myeloid leukemia, Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}